BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 21836511)

  • 21. Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction.
    Paoletti E; Ratto E; Bellino D; Marsano L; Cassottana P; Cannella G
    J Nephrol; 2012; 25(5):709-18. PubMed ID: 22038336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal.
    Doesch AO; Müller S; Konstandin M; Celik S; Kristen A; Frankenstein L; Ehlermann P; Sack FU; Katus HA; Dengler TJ
    Transplant Proc; 2010 Nov; 42(9):3694-9. PubMed ID: 21094840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcineurin inhibitor withdrawal and conversion to mycophenolate mofetil and steroids in cardiac transplant recipients with chronic renal failure: a word of caution.
    Groetzner J; Kaczmarek I; Schirmer J; Uberfuhr P; Gulbins H; Daebritz S; Meiser B; Reichart B
    Clin Transplant; 2008; 22(5):587-93. PubMed ID: 18460000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcineurin-inhibitor avoidance in elderly renal allograft recipients using ATG and basiliximab combined with mycophenolate mofetil.
    Guba M; Rentsch M; Wimmer CD; Uemueksuez A; Illner WD; Schönermarck U; Land WG; Jauch KW; Arbogast H
    Transpl Int; 2008 Jul; 21(7):637-45. PubMed ID: 18282242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study.
    Burkhalter F; Oettl T; Descoeudres B; Bachmann A; Guerke L; Mihatsch MJ; Dickenmann M; Steiger J
    Transplant Proc; 2012 Dec; 44(10):2961-5. PubMed ID: 23195006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience.
    Lobach NE; Pollock-Barziv SM; West LJ; Dipchand AI
    J Heart Lung Transplant; 2005 Feb; 24(2):184-9. PubMed ID: 15701435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Empiric switch from calcineurin inhibitor to sirolimus-based immunosuppression in pediatric heart transplantation recipients.
    Loar RW; Driscoll DJ; Kushwaha SS; Cramer CH; O'Leary PW; Daly RC; Mauriello DA; Johnson JN
    Pediatr Transplant; 2013 Dec; 17(8):794-9. PubMed ID: 24164828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcineurin Inhibitor Free De Novo Immunosuppression in Liver Transplant Recipients With Pretransplant Renal Impairment: Results of a Pilot Study (PATRON07).
    Schnitzbauer AA; Sothmann J; Baier L; Bein T; Geissler EK; Scherer MN; Schlitt HJ
    Transplantation; 2015 Dec; 99(12):2565-75. PubMed ID: 26018348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sirolimus monotherapy versus sirolimus in combination with steroids and/or MMF for immunosuppression after liver transplantation.
    Maheshwari A; Torbenson MS; Thuluvath PJ
    Dig Dis Sci; 2006 Oct; 51(10):1677-84. PubMed ID: 16964550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK; Huh KH; Ha J; Kim YH; Kim YL; Kim YS
    Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimizing the immunosuppressive regimen in heart transplantation.
    Eisen H; Ross H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
    Zucker MJ; Baran DA; Arroyo LH; Goldstein DJ; Neacy C; Mele L; Weinberg AD; Prendergast TW; Ribner HS
    Transplant Proc; 2005 Jun; 37(5):2231-9. PubMed ID: 15964386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Sirolimus use in heart transplantation recipients with chronic renal dysfunction].
    Yin D; Huang J; Feng L; Liao ZK; Feng GX; Wang W; Song YH; Hu SS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Feb; 40(2):136-40. PubMed ID: 22490714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression.
    Flechner SM; Feng J; Mastroianni B; Savas K; Arnovitz J; Moneim H; Modlin CS; Goldfarb D; Cook DJ; Novick AC
    Transplantation; 2005 Apr; 79(8):926-34. PubMed ID: 15849545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity.
    Höcker B; Feneberg R; Köpf S; Weber LT; Waldherr R; Wühl E; Tönshoff B
    Pediatr Transplant; 2006 Aug; 10(5):593-601. PubMed ID: 16856996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
    Herlenius G; Felldin M; Nordén G; Olausson M; Bäckman L; Gustafsson B; Friman S
    Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in a cardiac transplant patient with chronic renal failure.
    Groetzner J; Kaczmarek I; Meiser B; Müller M; Daebritz S; Reichart B
    J Heart Lung Transplant; 2004 Jun; 23(6):770-3. PubMed ID: 15366440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
    Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
    Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Everolimus plus mycophenolate mofetil as initial immunosuppression in liver transplantation.
    Jiménez-Pérez M; González Grande R; Rando Muñoz FJ; de la Cruz Lombardo J; Muñoz Suárez MA; Fernández Aguilar JL; Pérez Daga JA; Santoyo-Santoyo J; Manteca González R; Rodrigo López JM
    Transplant Proc; 2015; 47(1):90-2. PubMed ID: 25645779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.